Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.
Mannis GN., Abboud CN., Daver NG., Murthy GSG., Wang ES., Bradley TJ., Yaghmour G., Vachhani P., Balasubramanian SK., Chua CC., Fong CY., Asch AS., Dong M., Li S., Bagheri T., Doshi P., Vyas P., Malki MMA.
INTRODUCTION: This phase 2 study evaluated magrolimab+venetoclax (VEN)+azacitidine (AZA) in untreated, unfit acute myeloid leukaemia (AML) and magrolimab+mitoxantrone+etoposide+cytarabine in relapsed/refractory (R/R) AML. METHODS: Endpoints included complete remission rate (CRR), overall response rate (ORR), overall survival (OS) and safety. RESULTS: Eighteen and 36 patients were enrolled into the unfit and R/R AML arms, respectively. CRR was 38.9% and 25.0%, ORR was 66.7% and 38.9%, and median OS was 15.3 and 10.5 months in the unfit AML and R/R AML arms, respectively. No dose-limiting toxicities or magrolimab-related deaths occurred. CONCLUSION: Magrolimab was safely combined with existing AML therapies with no new safety signals. CLINICAL TRIAL REGISTRATION: This trail was registered at www.clinicaltrials.gov as NCT04778410.